poisar

Stocks · News reference

Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target

Benzinga Newsdesk

Needham analyst Ami Fadia reiterates Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and maintains $50 price target.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

HRMY
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth

    Harmony Biosciences reported Q3 EPS of 81 cents, missing consensus estimates of $1.00, despite 12% revenue growth to $269 million. Higher R&D spending, a $25 million MSN milestone charge, and royalty expenses pressured profitability. The company reaffirmed its 2026 Wakix revenue guidance of $1-$1.04 billion, supported by sustained patient demand and 400 net patient additions. The pipeline includes promising Phase I results for BP-205 and ongoing late-stage studies for pitolisant formulations and epilepsy programs.

    HRMYTAKTGTXTARS
  5. SEC EDGAR

    8-K/A filing — Harmony Biosciences Holdings, Inc. (HRMY)

    Filed: 2026-10-30 AccNo: 0001104659-26-120673 Size: 495 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

    HRMY
  6. Delveinsight

    Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsight

    Over 60 pharmaceutical companies are advancing more than 65 medical marijuana pipeline therapies across multiple clinical development stages. Key players including Harmony Biosciences, Cardiol Therapeutics, Incannex Healthcare, and others are developing treatments for conditions ranging from chronic pain and neurological disorders to psychiatric conditions. Recent milestones include FDA approvals for Exilby (first European cannabis-based chronic pain treatment) and Syndros, with several Phase III trials underway for conditions like Fragile X Syndrome, autism spectrum disorder, and obstructive sleep apnea.

    HRMYCRDLIXHL